original articleshematologic malignanciesPatients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes
hematologic malignancies
Under an Elsevier user license
open archive
Key words
mantle cell lymphoma
treatment
ibrutinib
Bruton's tyrosine kinase inhibitors
prognosis
Cited by (0)
Copyright © 2015 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.